NAT1 and cancer: In humans, besides their influence on the effectiveness of prescribed medications, polymorphisms at NAT2, and also at NAT1, have been associated with differential susceptibility to various cancers linked to arylamine exposure (Hein 2002; Agundez 2008b; Ladero 2008; Selinski et al. 2015; Hein 2018; Laurieri et al. 2018).